Powder: -20°C for 3 years | In solvent: -80°C for 1 year
LCS3 is a reversible and non-competitive synergistic inhibitor of glutathione disulfide reductase (GSR) and thioredoxin reductase 1 (TXNRD1) with IC50s of 3.3 μM and 3.8 μM, respectively. LCS3 has antitumour activity, induces apoptosis and can be used in the study of lung adenocarcinoma (LUAD).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 51.00 | |
5 mg | In stock | $ 122.00 | |
10 mg | In stock | $ 197.00 | |
25 mg | In stock | $ 455.00 | |
50 mg | In stock | $ 672.00 | |
100 mg | In stock | $ 956.00 | |
500 mg | In stock | $ 1,920.00 |
Description | LCS3 is a reversible and non-competitive synergistic inhibitor of glutathione disulfide reductase (GSR) and thioredoxin reductase 1 (TXNRD1) with IC50s of 3.3 μM and 3.8 μM, respectively. LCS3 has antitumour activity, induces apoptosis and can be used in the study of lung adenocarcinoma (LUAD). |
Targets&IC50 | GSR:3.3 µM, TXNRD1:3.8 µM, M. tuberculosis:0.098 µM(MIC) |
In vitro |
LCS3 (5 nM-10 µM ; 96 h) effectively inhibits lung cancer cell lines, while non-transformed lung cells show no signs of inhibition.[1] LCS3 (3 µM ; 3, 6, and 12 h) induces ROS and NRF2 pathway activation in sensitive lung adenocarcinoma (LUAD) cells.[1] LCS3 (3 µM ; 96 h) selectively kills lung adenocarcinoma (LUAD) cell lines, in part through the induction of apoptosis.[1] |
Molecular Weight | 266.64 |
Formula | C11H7ClN2O4 |
CAS No. | 109844-92-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 112.5 mg/mL (421.9 mM), Sonication and heating to 60℃ are recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
LCS3 109844-92-0 Apoptosis oxidation-reduction Glutathione reductase inhibitor inhibit